Osamu Ishimoto

1.4k total citations · 1 hit paper
34 papers, 995 citations indexed

About

Osamu Ishimoto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Osamu Ishimoto has authored 34 papers receiving a total of 995 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Osamu Ishimoto's work include Lung Cancer Research Studies (20 papers), Lung Cancer Treatments and Mutations (16 papers) and Cancer therapeutics and mechanisms (8 papers). Osamu Ishimoto is often cited by papers focused on Lung Cancer Research Studies (20 papers), Lung Cancer Treatments and Mutations (16 papers) and Cancer therapeutics and mechanisms (8 papers). Osamu Ishimoto collaborates with scholars based in Japan, United Kingdom and Canada. Osamu Ishimoto's co-authors include Toshihiro Nukiwa, Shuntaro Ikawa, Chikashi Kawahara, Masuo Obinata, Kentaro Enjo, Motoko Tachihara, Nobuyuki Yamamoto, Hiroshi Sakai, Koichi Takayama and Hiroshi Nokihara and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and The Lancet Oncology.

In The Last Decade

Osamu Ishimoto

33 papers receiving 974 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

2017 308 citations Toshiaki Takahashi, Takeharu Yamanaka et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Osamu Ishimoto Japan	11	795	480	439	354	83	34	995
Suchita Pakkala United States	15	685 0.9×	522 1.1×	106 0.2×	154 0.4×	20 0.2×	32	973
Anya M. Litvak United States	12	596 0.7×	243 0.5×	335 0.8×	233 0.7×	36 0.4×	15	900
Joseph Ayoub Canada	17	567 0.7×	411 0.9×	191 0.4×	485 1.4×	8 0.1×	26	1.1k
Lionel Bosquée Belgium	18	415 0.5×	514 1.1×	121 0.3×	192 0.5×	12 0.1×	39	811
Tsukihisa Yoshida Japan	14	377 0.5×	456 0.9×	72 0.2×	122 0.3×	17 0.2×	34	650
K Karrer Austria	13	504 0.6×	270 0.6×	348 0.8×	161 0.5×	29 0.3×	84	718
Lynnette Fernandez‐Cuesta France	13	501 0.6×	189 0.4×	341 0.8×	160 0.5×	26 0.3×	29	699
Ernst de Bruijn Belgium	14	281 0.4×	135 0.3×	84 0.2×	98 0.3×	78 0.9×	22	561
Sherif Y. El Sharouni Netherlands	10	498 0.6×	456 0.9×	305 0.7×	111 0.3×	5 0.1×	26	728
Christian Monnerat Switzerland	14	361 0.5×	190 0.4×	106 0.2×	187 0.5×	10 0.1×	34	645

Countries citing papers authored by Osamu Ishimoto

Since Specialization

Citations

This map shows the geographic impact of Osamu Ishimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Osamu Ishimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Osamu Ishimoto more than expected).

Fields of papers citing papers by Osamu Ishimoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Osamu Ishimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Osamu Ishimoto. The network helps show where Osamu Ishimoto may publish in the future.

Co-authorship network of co-authors of Osamu Ishimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Osamu Ishimoto. A scholar is included among the top collaborators of Osamu Ishimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Osamu Ishimoto. Osamu Ishimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kawashima, Yosuke, Osamu Ishimoto, Eisaku Miyauchi, et al.. (2023). Phase II trial of daily S‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101. Thoracic Cancer. 14(27). 2804–2810. 1 indexed citations

Shukuya, Takehito, Ryo Ko, Yusuke Okuma, et al.. (2022). Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study. Cancers. 14(2). 331–331. 2 indexed citations

Watanabe, Satoshi, Ou Yamaguchi, Yosuke Kawashima, et al.. (2018). Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs. Anticancer Research. 38(8). 4699–4704. 7 indexed citations

Takahashi, Toshiaki, Takeharu Yamanaka, Takashi Seto, et al.. (2017). Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 18(5). 663–671. 308 indexed citations breakdown →

Ishimoto, Osamu, Shunichi Sugawara, Akira Inoue, Makoto Maemondo, & Toshihiro Nukiwa. (2015). Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study. Respiratory Investigation. 53(4). 156–160. 3 indexed citations

Kawashima, Yosuke, Akira Inoue, Shunichi Sugawara, et al.. (2014). Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802. Respiratory Investigation. 52(3). 190–194. 3 indexed citations

Matsumoto, Yoshifumi, Makoto Maemondo, Yoshiki Ishii, et al.. (2014). A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: Re-evaluation of EGFR gene status (NEJ006/TCOG0903). Lung Cancer. 86(2). 195–200. 7 indexed citations

Sugawara, Shunichi, Makoto Maemondo, Motoko Tachihara, et al.. (2013). Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601. Lung Cancer. 81(1). 91–96. 18 indexed citations

Saito, Ryota, Akira Inoue, Shunichi Sugawara, et al.. (2012). Phase II study of amrubicin (AMR) combined with carboplatin (CBDCA) for refractory relapsed small cell lung cancer (SCLC): North Japan Lung Cancer Group 0802.. Journal of Clinical Oncology. 30(15_suppl). 7086–7086. 1 indexed citations

10.

Maemondo, Makoto, Akira Inoue, Osamu Ishimoto, et al.. (2012). A phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703. Respiratory Investigation. 51(1). 28–34. 9 indexed citations

11.

Inoue, Akira, Osamu Ishimoto, Shinichi Fukumoto, et al.. (2009). A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405. Annals of Oncology. 21(4). 800–803. 27 indexed citations

12.

Ishimoto, Osamu, Takashi Ishida, Yoshihiro Honda, Mitsuru Munakata, & Shunichi Sugawara. (2009). Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer. International Journal of Clinical Oncology. 14(1). 43–47. 8 indexed citations

13.

Inoue, Akira, Shunichi Sugawara, Koichi Yamazaki, et al.. (2008). Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402. Journal of Clinical Oncology. 26(33). 5401–5406. 188 indexed citations

14.

Sakakibara, Tomohiro, Yasuo Saijo, Tatsuro Fukuhara, et al.. (2008). Adenocarcinoma With Epidermal Growth Factor Receptor Gene Mutations in Three Siblings. Journal of Thoracic Oncology. 3(3). 311–313. 1 indexed citations

15.

Inoue, Akira, Kazuhiro Usui, Osamu Ishimoto, et al.. (2006). A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer. Lung Cancer. 52(1). 83–87. 20 indexed citations

16.

Tazawa, Ryushi, Emi Hamano, Toru Arai, et al.. (2005). Granulocyte-Macrophage Colony–Stimulating Factor and Lung Immunity in Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine. 171(10). 1142–1149. 77 indexed citations

17.

Usui, Kazuhiro, et al.. (2005). A phase II trial of weekly paclitaxel and carboplatin for elderly patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 23(16_suppl). 7248–7248. 5 indexed citations

18.

Ishimoto, Osamu, Yasuo Saijo, Yuichiro Kimura, et al.. (2002). High Level of Vascular Endothelial Growth Factor in Hemorrhagic Pleural Effusion of Cancer. Oncology. 63(1). 70–75. 40 indexed citations

19.

Tani, Masachika, Kimihiro Shimizu, Chikashi Kawahara, et al.. (1999). Mutation and Expression of the p51 Gene in Human Lung Cancer. Neoplasia. 1(1). 71–79. 25 indexed citations

20.

Morita, Tatsuya, J Tsunoda, Shin‐ichiro Inoue, et al.. (1998). [Prediction of survival of terminally ill cancer patients--a prospective study].. PubMed. 25(8). 1203–11. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact